Molecular Partners AG (NASDAQ:MOLN – Get Free Report) shares were up 5.5% on Thursday . The company traded as high as $4.66 and last traded at $4.66. Approximately 2,515 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 26,157 shares. The stock had previously closed at $4.41. Analyst […]
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of.
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities.
Molecular Partners (NASDAQ:MOLN – Get Free Report) is one of 286 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Molecular Partners to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends. Volatility […]
New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions.